KIT is a receptor tyrosine kinase whose gain-of-function mutations act as a key driver in most gastrointestinal stromal tumors (GIST). Testing for C-KIT alterations is therefore central both to diagnosis and to tracking why a tumor may stop responding to targeted therapy. This article focuses on the resistance angle: how KIT mutation status evolves during treatment and why repeated testing can inform the next clinical step.
Most GISTs carry a primary KIT mutation, with exon 11 being the most common site, and these tumors generally respond to the first-line tyrosine kinase inhibitor imatinib. Resistance, however, is common: in the majority of patients, the cancer re-grows within two to three years as the tumor acquires secondary KIT mutations. These secondary changes cluster in the ATP-binding pocket (exons 13 and 14) or the activation loop (exons 17 and 18), altering the kinase shape so imatinib can no longer bind effectively.
A C-KIT mutation test performed on a progressing lesion detects these emerging variants. Because different secondary mutations retain or lose sensitivity to later-line inhibitors such as sunitinib or regorafenib, the specific mutation pattern helps explain why one agent worked and the next may not.
When a secondary KIT mutation is found, the team can match the resistance profile to an alternative inhibitor rather than repeating a failing regimen. Testing also confirms that progression is truly driven by KIT evolution rather than an unrelated mechanism, which keeps therapy selection precise. In this way, C-KIT testing turns a vague "treatment stopped working" into an actionable, mutation-defined decision.
Q: Is C-KIT testing done on the tumor or on blood?
A: Resistance testing is performed on a tumor sample from the progressing lesion, because secondary mutations appear in the cancer tissue, not in germline DNA.
Q: Why do secondary KIT mutations cause imatinib failure?
A: They reshape the kinase so the drug can no longer occupy its binding pocket, restoring signaling that drives tumor growth.
Q: How often does resistance develop in KIT-mutant GIST?
A: Acquired resistance emerges in the majority of patients within a few years, which is why monitoring and later-line planning matter.
Q: Does a KIT test replace broader GIST testing?
A: It is one part of the picture; PDGFRA and other drivers are also assessed when the initial KIT result is wild-type.
KIT is a receptor tyrosine kinase whose gain-of-function mutations act as a key driver in most gastrointestinal stromal tumors (GIST). Testing for C-KIT alterations is therefore central both to diagnosis and to tracking why a tumor may stop responding to targeted therapy. This article focuses on the resistance angle: how KIT mutation status evolves during treatment and why repeated testing can inform the next clinical step.
Most GISTs carry a primary KIT mutation, with exon 11 being the most common site, and these tumors generally respond to the first-line tyrosine kinase inhibitor imatinib. Resistance, however, is common: in the majority of patients, the cancer re-grows within two to three years as the tumor acquires secondary KIT mutations. These secondary changes cluster in the ATP-binding pocket (exons 13 and 14) or the activation loop (exons 17 and 18), altering the kinase shape so imatinib can no longer bind effectively.
A C-KIT mutation test performed on a progressing lesion detects these emerging variants. Because different secondary mutations retain or lose sensitivity to later-line inhibitors such as sunitinib or regorafenib, the specific mutation pattern helps explain why one agent worked and the next may not.
When a secondary KIT mutation is found, the team can match the resistance profile to an alternative inhibitor rather than repeating a failing regimen. Testing also confirms that progression is truly driven by KIT evolution rather than an unrelated mechanism, which keeps therapy selection precise. In this way, C-KIT testing turns a vague "treatment stopped working" into an actionable, mutation-defined decision.
Q: Is C-KIT testing done on the tumor or on blood?
A: Resistance testing is performed on a tumor sample from the progressing lesion, because secondary mutations appear in the cancer tissue, not in germline DNA.
Q: Why do secondary KIT mutations cause imatinib failure?
A: They reshape the kinase so the drug can no longer occupy its binding pocket, restoring signaling that drives tumor growth.
Q: How often does resistance develop in KIT-mutant GIST?
A: Acquired resistance emerges in the majority of patients within a few years, which is why monitoring and later-line planning matter.
Q: Does a KIT test replace broader GIST testing?
A: It is one part of the picture; PDGFRA and other drivers are also assessed when the initial KIT result is wild-type.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
